Jazz Pharmaceuticals prices $1.1B convertible note offering
What's the deal? Jazz Pharmaceuticals has priced an upsized private offering of $1.1 billion in 1.875% exchangeable senior notes due 2032. The notes were issued by wholly owned subsidiary Jazz Investments I LimitedDealroom has a profile for this one. Try Dealroom → to qualified institutional buyers, with a 13-day option for initial purchasers to buy up to $150 million more. The sale is expected to close on August 31, 2026.
Why now? The Nasdaq-listed drugmaker upsized the offering from a previously announced $1 billion, tapping investor appetite for its debt at a low coupon. The notes carry a 1.875% annual interest rate and mature on September 15, 2032.
What's the endgame? Net proceeds are estimated at $1,079 million, or $1,226.4 million if the option is fully exercised, earmarked for general corporate purposes. Concurrently, Jazz agreed to repurchase about $225 million of its ordinary shares at $249.29 each, funded from existing cash under its July 2024 buyback program.
The fine print: The notes are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 — an exchange price of roughly $355.24, a 42.5% premium to the August 26, 2026 close. Upon exchange, the issuer pays cash up to principal and may settle any excess in cash, shares, or both. The notes are senior unsecured obligations, fully guaranteed by Jazz Pharmaceuticals.
What could go wrong? The deal adds $1.1 billion in debt and carries potential future dilution if holders exchange into ordinary shares. The buyback also draws down available cash.
The signal: The raise ranks in the 96th percentile by size among post-IPO convertible rounds over the trailing 48 months, across a sample of 1,834 deals. Pairing a large, cheap convertible with a concurrent buyback lets Jazz lock in low-cost financing while cushioning near-term dilution — a playbook increasingly favoured by cash-generative companies with elevated share prices.
Read more: stocktitan.net
Image credit: Generated with Gemini
